International name: Immunoglobulin
against cytomegalovirus (Immunoglobulin cytomegalovirus).
Pharmacological properties Tsitotekta
Human immunoglobulin contains specific antibodies (mainly IgG), directed against the pathogen cytomegalovirus.
Tsitotekt used for the prevention and treatment of cytomegalovirus infection in patients with suppressed immune system, which the immune system has been suppressed for organ transplants.
For the treatment of CMV infection in immunocompromised due to other causes, such as HIV infection.
Individual intolerance of human immunoglobulin.
Injectable solution must be heated to a temperature at least 22 ° C, or at body temperature. The infusion rate should not exceed 20 drops / min. Before administration must ensure no discoloration and no particles suspended in solution in the presence of signs of data, according to instructions Tsitotekt can not enter.
A single dose of 50 IU / kg. Patients undergoing transplantation is introduced 1 ml / kg, starting from the day of surgery, and bone marrow transplantation administration of the preparation begins the day before surgery. Prophylactic administration Tsitotekta begins 10 days before the transplant operation. Preliminary reception Tsitotekta especially important for CMV seropositive patients who should receive no less than 6 doses with an interval of 2-3 weeks.
In the treatment of infections introduced not less than 2 ml / kg every two days until symptoms disappear.
In the treatment of cytomegalovirus infection minimum single dose of 100 U / kg of body weight, taken at intervals of 48 hours.
Most often an overdose occurs in patients who are overweight, elderly, and those with impaired renal function (including patients with diabetes).
Overdosing elderly patients and patients with reduced renal function can cause hyperviscosity of blood and fluid overload. Where there is evidence of cardiac or cerebral ischemia, an increase in blood viscosity can cause complications. In this regard, these groups must not be exceeded daily dose of 8 ml / kg body weight.
After receiving Tsitotekta necessary to control the content of creatine daily for 3 days.
Side effects Tsitotekta
The application can be Tsitotekta side effects such as: headache, chills, nausea, fever, vomiting, mild pain in the back, aching joints, and allergic reactions.
In rare cases, particularly at high doses of intravenous immunoglobulin, recorded cases of symptoms of aseptic meningitis, such as nausea, fever, vomiting, severe headache, neck stiffness, impaired consciousness, photosensitivity. Particular care should be exercised when treating patients Tsitotektom prone to migraines.
Reported from isolated cases, when
in patients with impaired renal function may occur exacerbation of renal failure until anuria. Symptoms may occur with large doses Tsitotekta and disappear after cessation of treatment.
Sometimes Tsitotekta side effect can be a decrease in blood pressure and, rarely, anaphylactic shock. If anaphylactic reactions being treated in accordance with the regulations of shock therapy.
Pregnancy and lactation
Clinically controlled trials of pregnant Tsitotekta not been so Tsitotekta use during pregnancy and breastfeeding should be done with caution. Long experience in the medical use of antibodies indicates that the harmful effects on pregnancy, fetal development and newborn unlikely. Immunoglobulins partly derived from breast milk and may cause transfer of antibodies to the child.
The probability of side effects depends on the rate of administration. By increasing the rate of infusion growing number of side effects, so it is important to observe the speed of administration, recommended instruction Tsitotekta. The patient throughout the process of infusion should be under the supervision of a physician for early detection of possible symptoms of side effects.
The first application Tsitotekta manifestation of minor side effects observed more frequently than in patients receiving the drug regularly. Therefore, after the first infusion is necessary to continue monitoring the patient for at least one hour, and subsequent infusions of up to 20 minutes after cessation of Tsitotekta.
Indications that immunoglobulins affect the ability to drive vehicles, has been received.
Interaction with other drugs Tsitotekta
Immunoglobulins may have a negative effect of 1, 5 to 3 months to live virus vaccines such as measles, rubella, chickenpox, mumps. At high doses Tsitotekta, its impact on the live virus vaccine can be tracked for one year.
Acceptable mixing Tsitotekta 0, 9% sodium chloride solution. The addition of other drugs in solution Tsitotekta instruction is unacceptable as it can cause a pH change or level of electrolyte concentration, which in turn may result in precipitation or denaturation of the protein.
Storage conditions Tsitotekta
Tsitotekt should be stored at temperature 2-8 ° C in a place protected from light. Frosting Tsitotekt impossible. The preparation of opening the bottle or vials must be used immediately. Remains of the solution because of the risk of bacterial contamination should be discarded.
2 years. After the specified expiry date on the packaging should be disposed Tsitotekt.